B+
Bull case
0%
Probability
Target price
$300.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
COR
CencoraDNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
The strongest post-print argument is that the market can look past a modest consensus miss because the company raised FY2026 adjusted EPS guidance to $17.65-$17.90, cited strong U.S. Healthcare Solutions operating-income growth, and showed OneOncology already helping mix and gross profit [#8-K-2026-05-06].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +6.8.
What can break
Acquisition financing materially increased debt: total debt rose to about $12.4 billion at March 31, 2026 from about $7.7 billion at September 30, 2025, raising interest-cost sensitivity after OneOncology [#10-Q-2026-05-06].
Momentum
50
Value
64
Sentiment
45
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $275.00 · Bull $300.00 · Bear $235.00Analysis 2026-05-08; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $368.92
Why
Momentum50 · Δ7d +11.2
Value64 · Δ7d -0.0
Sentiment45 · Δ7d +6.8
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +6.8.
Contradictions & invalidation
- • Acquisition financing materially increased debt: total debt rose to about $12.4 billion at March 31, 2026 from about $7.7 billion at September 30, 2025, raising interest-cost sensitivity after OneOncology [#10-Q-2026-05-06].
- • Adjusted EPS and revenue both missed consensus in immediate post-earnings coverage, which can cap multiple expansion even after a guidance raise.
- • The main bear read is that the quarter still missed consensus on both EPS and revenue based on AP/Zacks figures, while the operational bridge includes lower manufacturer prices on some brands, weaker large mail-order sales from brand conversions, and the lingering effect of a lost oncology customer; that makes the raised guide more dependent on integration and mix staying favorable than the headline may suggest.
Catalyst clock
2026-05-14
Q2 print raised FY2026 adjusted EPS guide despite a small headline miss
Lead driver: Sentiment · See AI snapshot
Momentum
50
9% active weight
Current posture
7d trendImproving
Δ7d
+11.2
Δ21d
-2.9
Value
64
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+5.2
Sentiment
45
62% active weight
Current posture
7d trendImproving
Δ7d
+6.8
Δ21d
-0.8
Why this grade
Composite grade D. Momentum 49.8 / Value 64.0 / Sentiment 44.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-08. Scenario method
Most likely
B
Base case
1%
Probability
Target price
$275.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$235.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$59.64B
Beta
0.68
Shares Out
190.83M
P/E (TTM)
42.9
P/S (TTM)
0.21
P/FCF (TTM)
23.88
Rev YoY
+5.1%
EPS YoY
+11.8%
Gross Margin
+3.6%
Op Margin
+1.3%
Net Debt
$4.94B
Current Ratio
0.93
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data